Clinical Trials Directory

Trials / Unknown

UnknownNCT05448430

iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.

iTBS Can Increase Frontal Dopamine Release and Improve Glucose Metabolism in PET Dopamine Imaging of Patients With Schizophrenia.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Central South University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Aim: 1. To confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2\. Our previous study found patients with negative symptoms have more possibilities to have disorders in glucose metabolism, we wonder whether dopamine release, negative symptoms or glucose metabolism can be improved by iTBS. Study design: Case control study.

Detailed description

Eligibility Criteria: Predominant negative symptoms for Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or more, and score of 4 or more on at least two of three core negative PANSS items, PANSS for positive symptoms of 19 or less, HAMD depression scale of 16 or less. Predominant positive symptoms for PANSS for positive symptoms of 20 or more. Healthy control will be recruited matching the age and sex of patient groups, Outcome Measures: Oral glucose tolerance test (OGTT), PET dopamine imaging.

Conditions

Interventions

TypeNameDescription
DEVICETheta burst stimulationa new paradigm of high frequency repetitive transcranial magnetic stimulation

Timeline

Start date
2022-07-15
Primary completion
2024-07-01
Completion
2024-07-01
First posted
2022-07-07
Last updated
2022-07-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05448430. Inclusion in this directory is not an endorsement.